Search

Current pharmaceutical development often treats formulation design, process control, and patient-focused performance as sequential domains rather than mutually dependent components of one technology system. This separation can produce technically elegant formulations that are difficult to manufacture, tightly controlled processes that do not fully serve patient needs, or patient-friendly dosage forms that lack robust process translation. A systems perspective is therefore needed to connect product intent, manufacturing feasibility, and real-world usability from the earliest stages of development. The central problem is the absence of an integrated theory that explains how formulation decisions, process control strategies, and patient-centric targets should be co-optimised. Existing development pathways often allow these domains to interact only after critical decisions have already been made. This creates avoidable friction during scale-up, regulatory justification, and clinical implementation. The objective of this article is to propose a theory-driven systems framework for applied pharmaceutical technologies. The framework integrates formulation design logic, process control logic, and patient-centric performance into a unified conceptual model. It is intended to guide early decision-making, cross-functional communication, and translational planning. The resulting framework identifies three interacting pillars: formulation design as the material and biopharmaceutical architecture of the product, process control as the mechanism for assuring reproducible quality, and patient-centric performance as the translation of product attributes into acceptability, adherence, and therapeutic usability. Four tables capture the formulation parameters, process control strategies, patient-centric targets, and integrated framework components. Together, these elements define a systems logic for pharmaceutical technology development. The proposed framework provides a conceptual blueprint for developing pharmaceutical products that are simultaneously manufacturable, quality-assured, and optimised for patients. It supports earlier recognition of trade-offs, clearer integration of predictive models, and stronger alignment between development choices and clinical use. Its broader value lies in reframing pharmaceutical technology as a patient-anchored system rather than a sequence of isolated technical operations.

The translation of drug delivery innovations from laboratory design to clinical application remains uncertain, expensive, and highly selective. Many systems demonstrate promising biological activity in early studies but fail to progress because evidence of manufacturability, safety, stability, or regulatory maturity is incomplete. This creates a recurring gap between technical novelty and clinical readiness. Existing technology readiness models provide useful language for describing maturity, but they were not originally designed for pharmaceutical technologies. Drug delivery systems require simultaneous assessment of material attributes, formulation behaviour, biological performance, dose reproducibility, scale-up potential, and patient-facing utility. A single linear maturity scale is therefore insufficient for classifying readiness before first-in-human development. This article develops a novel conceptual model called the Pharmaceutical Technology Readiness Matrix. The model integrates technology readiness logic, drug delivery innovation categories, and preclinical translation criteria into a structured assessment framework. Its purpose is to support transparent classification, risk assessment, and decision-making before clinical translation. The proposed matrix adapts readiness levels for drug delivery technologies, classifies major innovation categories, defines preclinical translation criteria, and links evidence maturity to risk and Go/No-Go decisions. Five tables specify the readiness levels, innovation categories, translation criteria, matrix design, and decision pathway. Together, these elements provide a practical conceptual tool for comparing heterogeneous delivery technologies. The Pharmaceutical Technology Readiness Matrix may help researchers, investors, developers, and regulators evaluate drug delivery systems more consistently. By making evidence gaps explicit before clinical translation, the model aims to reduce avoidable attrition and guide rational allocation of development resources. Future empirical validation will be required to test its predictive value across delivery platforms and therapeutic areas.

Algorithmic tools are becoming embedded in pharmaceutical technology development, from formulation screening and excipient selection to process modelling, scale-up prediction, analytical method optimisation, and manufacturing control. These tools increasingly influence decisions that were historically made through human expert judgement, experimental iteration, and quality-system review. This shift creates a governance challenge because algorithmic recommendations may affect product quality, process robustness, patient safety, and regulatory compliance. Yet accountability for such decisions is often distributed ambiguously across data scientists, formulation scientists, process engineers, quality assurance units, regulatory teams, software vendors, and corporate management. The objective of this article is to construct an original governance framework for accountable algorithmic decision-making in pharmaceutical technology development. The framework is designed for settings where artificial intelligence, machine learning, and related computational decision-support tools influence formulation, process, analytical, or quality decisions. The proposed framework argues that accountability must be designed into algorithmic pharmaceutical development rather than retrofitted after model deployment. It defines algorithmic decision types, clarifies accountability triggers, and positions governance as part of the pharmaceutical quality system rather than as a separate digital compliance layer.

Pharmaceutical technologies are commonly designed and validated under controlled assumptions about materials, processes, supply continuity, and patient use. Yet once products enter development, scale-up, manufacturing, distribution, and real-world use, they encounter variability that cannot be fully predicted or eliminated. Supply disruptions, raw-material shifts, equipment drift, environmental fluctuations, and heterogeneous patient behaviours can all disturb the intended relationship between product design and therapeutic performance. The prevailing pharmaceutical design paradigm has made important advances through quality-by-design, risk management, and process analytical technology. However, it often treats variability primarily as a deviation from a predefined optimum rather than as a persistent condition of system operation. This creates a risk that pharmaceutical technologies become highly optimised for expected conditions but brittle when exposed to unfamiliar combinations of supply, process, and patient-level stressors. This article proposes an original resilience-theoretic framework for pharmaceutical technology design. The framework argues that technologies should be designed not only to meet specifications under normal conditions, but also to absorb disturbance, adapt to changing conditions, maintain acceptable performance, and degrade gracefully when ideal operation is no longer possible. It therefore reframes resilience as a design objective rather than a post hoc recovery capability. The article contributes a conceptual structure for aligning pharmaceutical technology design with the realities of variability. It shows how resilience thinking can connect supply robustness, process adaptability, and patient-centred performance into a single design logic. Designing for resilience represents a shift from static robustness toward dynamic adaptability, offering a pathway to pharmaceutical technologies that remain reliable, usable, and therapeutically meaningful under changing conditions.

Most pharmaceutical manufacturing technologies are conceived in environments where electricity, purified water, skilled operators, calibrated instruments, and validated supply chains are treated as stable background conditions. These assumptions shape equipment selection, process control, formulation strategy, packaging design, and quality assurance architecture. When such technologies are transferred unchanged into low-resource environments, the hidden dependence on high-resource infrastructure becomes visible. The central problem is not simply scarcity but design-context mismatch. Technologies that require continuous utilities, specialist maintenance, narrow environmental control, or complex analytical confirmation may produce avoidable quality deviations, production interruptions, and inequitable access. Low-resource manufacturing therefore requires a design logic that begins with constraints rather than adapting to them after failure. The proposed approach translates infrastructure, workforce, supply-chain, and quality-system constraints into design requirements. It argues for simple, robust, modular, maintainable, and environmentally tolerant technologies that preserve critical quality attributes without requiring fragile operating conditions. Three tables support the framework by cataloguing constraints, technology principles, and decision logic. Frugal pharmaceutical design is not a lowering of standards. It is a disciplined method for building quality into technologies that must function where conventional manufacturing assumptions do not hold. Its wider adoption requires pharmaceutical scientists, regulators, global health practitioners, and local manufacturers to treat low-resource design as a legitimate and necessary branch of pharmaceutical technology.

Advanced drug delivery systems promise more precise, durable, and patient-centred therapy through nanomedicines, long-acting formulations, implantable platforms, smart delivery devices, and personalised dosage forms. These technologies can reduce dosing burden, improve therapeutic control, and expand the design space of pharmaceutical care. Yet the same sophistication that makes them attractive can also make them expensive, infrastructure-dependent, and difficult to use. The equity implications of these technologies therefore require systematic attention. The central problem addressed in this article is that pharmaceutical innovation is often evaluated through performance, safety, manufacturability, and market value, while equity remains treated as a downstream access issue. This creates a risk that advanced drug delivery systems will reach populations already well served by health systems while excluding communities facing poverty, geographic isolation, disability, low literacy, weak infrastructure, or limited digital access. Equity cannot be repaired only after launch if exclusion has already been built into the technology. It must be considered during design, development, evaluation, pricing, procurement, and implementation. This article develops the concept of pharmaceutical technology equity as a deliberate design and policy goal for advanced drug delivery systems. It argues that equitable pharmaceutical technology requires simultaneous attention to access, affordability, and usability. Access concerns whether the technology can physically and institutionally reach the people who need it. Affordability concerns whether patients and health systems can obtain it without unacceptable financial burden, while usability concerns whether diverse users can safely and effectively engage with the product in real settings. The article defines pharmaceutical technology equity, identifies structural barriers, and proposes design principles for inclusive advanced drug delivery systems. Four tables support the argument by defining equity logic, cataloguing access barriers, mapping design principles, and presenting a decision-oriented framework. The core conclusion is that equity must become an explicit and measurable goal of pharmaceutical technology development. Advanced drug delivery should not merely produce better products for privileged users; it should expand therapeutic capability for populations historically excluded from high-value innovation.